The recovery culture here is occupational rather than athletic, and that makes it the least discussed and probably the most sympathetic version of this buyer in the metro. Nobody in Ermita is asking about BPC-157 because they want to add weight to a lift. They are asking because their heels hurt from the moment they get out of bed, because a knee that started complaining two years ago has stopped improving on days off, and because the alternative on offer is an anti-inflammatory taken often enough that they have started worrying about their stomach.
That last part is worth naming, because it is the corner of the research literature that speaks most directly to this district. The gastrointestinal work on BPC-157 includes animal studies on protection against damage from anti-inflammatory drugs and corticosteroids, alongside the brain-gut axis review literature. It is preclinical and rodent-based. It is not a human treatment, it is not a reason to keep taking anything that is upsetting your stomach, and a healthcare worker in this district has better access to a proper opinion on that than almost anyone.
The tendon side is the same evidence class: animal models, with rat Achilles detachment and tendon outgrowth work among the most cited experiments. BPC-157 is not registered with FDA Philippines, is not approved for human therapeutic use in this country, and there is nothing for anyone to prescribe. Every vial in Manila proper is research-grade material.